Advertisement
Advertisement
U.S. markets open in 4 hours 13 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Agile Therapeutics, Inc. (AGRX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.6415+0.0070 (+1.10%)
At close: 04:00PM EDT
0.6180 -0.02 (-3.66%)
Pre-Market: 05:11AM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close0.6345
Open0.6435
Bid0.0000 x 41800
Ask0.0000 x 1200
Day's Range0.6300 - 0.6700
52 Week Range0.4850 - 50.4000
Volume4,193,301
Avg. Volume10,961,943
Market Cap20.213M
Beta (5Y Monthly)1.22
PE Ratio (TTM)N/A
EPS (TTM)-26.1610
Earnings DateOct 31, 2022 - Nov 04, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for AGRX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Agile Therapeutics, Inc.
    Analyst Report: Merck & Co., Inc.Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, close to 40% of the firm's sales are generated in the United States.
    Rating
    Fair Value
    Economic Moat
    last yearMorningstar
View more
Advertisement
Advertisement